Suppr超能文献

肝毒清颗粒治疗普通感冒的疗效与安全性:一项多中心、随机、双盲、安慰剂对照试验

Efficacy and Safety of Ganduqing Granules in Treating the Common Cold: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.

作者信息

Wang Yilan, Zhou Piao, Wu Yuxiao, Cao Huaqin, Hao Wenfeng, Wang Fei, Guo Jing

机构信息

Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, Sichuan, China.

Community Health Service Center of Simaqiao, Chengdu 610084, Sichuan, China.

出版信息

Evid Based Complement Alternat Med. 2022 Jun 9;2022:5105503. doi: 10.1155/2022/5105503. eCollection 2022.

Abstract

BACKGROUND

There is no clear evidence-based medicine that points to the most effective drug treatments for the common cold. In view of its ability to relieve symptoms and shorten the disease course, as well as its minimal side effects, traditional Chinese medicine (TCM) has been widely used to treat the common cold. However, there is a lack of strong evidence to support the clinical efficacy of TCM. This study aimed to evaluate the efficacy and safety of Ganduqing granules in the treatment of the common cold based on the network pharmacology analysis.

METHODS

In this multicenter, randomized, double-blind, placebo-controlled trial, 60 eligible subjects will be randomly assigned to either the intervention group or the placebo group. The intervention group will be treated with Ganduqing granules, while the placebo group will be treated with placebo. After 5 days of intervention, the efficacy and safety of Ganduqing granules in the treatment of the common cold will be observed. The primary outcome is the time to clearance of all symptoms. The secondary outcomes included the levels of IL-6, TNF-, SOD, and MDA in the peripheral blood, time to disappearance of primary symptoms and secondary symptoms, clinical symptom remission rate, and change in TCM syndrome score.

RESULTS

Sixty participants completed the study. Ganduqing granules showed a greater effect on the time to clearance of all symptoms ( < 0.0001), nasal discharge (=0.0124), fatigue and lack of strength (=0.0138), dryness of the pharynx ( < 0.0001), pharyngalgia or dysphagia ( < 0.0001), and expectoration ( < 0.0431) compared with the placebo group. Participants in the intervention group had a greater decrease of IL-6 levels compared with the placebo group ( < 0.007); similar results were observed for the SOD ( < 0.033). However, the change in TNF- and MDA levels in the intervention group was not significantly different from the placebo group. In addition, participants in the intervention group had a greater decrease of TCM syndrome score compared with the placebo group ( < 0.040).

CONCLUSION

Ganduqing granules could improve common cold symptoms, shorten the disease course, attenuated inflammation and oxidative stress, and provided objective evidence for the efficacy and safety of a Chinese herbal medicine in treating the common cold.

摘要

背景

目前尚无明确的循证医学证据表明哪种药物对普通感冒最有效。鉴于中药能够缓解症状、缩短病程且副作用极小,其已被广泛用于治疗普通感冒。然而,缺乏有力证据支持中药的临床疗效。本研究旨在基于网络药理学分析评估感冒清热颗粒治疗普通感冒的疗效和安全性。

方法

在这项多中心、随机、双盲、安慰剂对照试验中,60名符合条件的受试者将被随机分配至干预组或安慰剂组。干预组服用感冒清热颗粒,安慰剂组服用安慰剂。干预5天后,观察感冒清热颗粒治疗普通感冒的疗效和安全性。主要结局指标为所有症状消失的时间。次要结局指标包括外周血中白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、超氧化物歧化酶(SOD)和丙二醛(MDA)的水平、主要症状和次要症状消失的时间、临床症状缓解率以及中医证候评分的变化。

结果

60名参与者完成了研究。与安慰剂组相比,感冒清热颗粒在所有症状消失时间(P<0.0001)、流涕(P=0.0124)、乏力(P=0.0138)、咽干(P<0.0001)、咽痛或吞咽困难(P<0.0001)以及咳痰(P<0.0431)方面显示出更大的疗效。与安慰剂组相比,干预组参与者的IL-6水平下降幅度更大(P<0.007);SOD水平也有类似结果(P<0.033)。然而,干预组TNF-α和MDA水平的变化与安慰剂组无显著差异。此外,与安慰剂组相比,干预组参与者的中医证候评分下降幅度更大(P<0.040)。

结论

感冒清热颗粒可改善普通感冒症状,缩短病程,减轻炎症和氧化应激,为一种中药治疗普通感冒的疗效和安全性提供了客观证据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c10/9203204/806491ceafbe/ECAM2022-5105503.001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验